Voyager Therapeutics
VYGR
132 hedge funds and large institutions have $331M invested in Voyager Therapeutics in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 56 increasing their positions, 29 reducing their positions, and 7 closing their positions.
371% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 7
93% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 29
44% more capital invested
Capital invested by funds: $230M → $331M (+$102M)
23% more funds holding
Funds holding: 107 → 132 (+25)
3.68% more ownership
Funds ownership: 61.81% → 65.49% (+3.7%)
17% less call options, than puts
Call options by funds: $579K | Put options by funds: $700K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.53M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.44M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.93M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.73M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.45M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.06M |
| 4 |
II
Inspire Investing
Meridian,
Idaho
|
-$802K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$797K |
VYGR Hedge Fund Activity: Q1 2024 in Review
132 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2024, worth a combined $331M — up 44% from $230M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VYGR positions and 7 closed out — a net gain of 26 holders — while 56 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $14.9M. The largest seller was Morgan Stanley, cutting an estimated $1.73M.
- 132 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2024, up from 107 in Q4 2023.
- Funds reported $331M of Voyager Therapeutics stock for Q1 2024, up 44% quarter-over-quarter.
- 33 funds opened new Voyager Therapeutics positions in Q1 2024 and 7 closed out, a net change of +26 holders.
- The largest Voyager Therapeutics buyer in Q1 2024 was BlackRock, an estimated $14.9M added.
- The largest Voyager Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $1.73M sold.
Based on aggregated 13F filings for Q1 2024.